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We have demonstrated that the S′1 and S′2 subsites of
human tissue kallikrein (hK1) play determinant roles in the
recognition and hydrolysis of substrates. The presence of
serine at position P′1 and arginine at P′2 resulted in the
best substrate, Abz-Ala-Ile-Lys-Phe-Phe-Ser-Arg-Gln-EDDnp,
which was derived from the kallistatin reactive-centre loop
sequence and quencher groups o-aminobenzoic acid (Abz)
and N-(2,4-dinitrophenyl)ethylenediamine (EDDnp). Serine and
arginine are also the residues at positions P′1 and P′2 in
human kininogen, from which hK1 releases Lys-bradykinin.
Several peptide analogues of Abz-Ala-Ile-Lys-Phe-Phe-Ser-Arg-
Gln-EDDnp, in which the Ser and Arg residues were substituted
with various other amino acids, were synthesized and tested as
substrates. Most of them were hydrolysed slowly, although they
showed significant binding to hK1, as demonstrated by their
competitive inhibition constants (K i). Using this information, six
peptides were designed, synthesized and assayed as inhibitors of
hK1. Abz-Lys-Phe-Phe-Pro-Arg-Gln-EDDnp, Abz-Lys-Phe-Arg-
Pro-Arg-Gln-EDDnp and acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH2
inhibited hK1 in the range 20–30 nM (letters in italics denote the
D-form of the amino acid). The peptide acetyl-Lys-Phe-Phe-Pro-
Leu-Glu-NH2 was a weak inhibitor for other serine proteases,
as indicated by the higher K i values compared with hK1, but
this peptide was a potent inhibitor of human plasma kallikrein,
which has a K i value of 8 nM. This result was surprising, since
this enzyme is known to be a restricted arginyl-hydrolase. In
conclusion, acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH2 can be used as
a leader compound to design specific inhibitors for hK1, plasma
kallikrein, or for both at same time, if the inhibition of kinin
release is the main goal.
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INTRODUCTION
Human tissue kallikrein (hK1) (EC 3.4.21.35) is a member of
a family of three closely related serine proteases [1,2], which
includes two enzymes expressed in prostate, namely prostate-
specific antigen (PSA; also called hK3) and a trypsin-like enzyme,
hK2. This classical view has been altered by the inclusion of
14 genes in the human kallikrein gene family, some of which
have been correlated with carcinogenesis [3]. hK1 is the only
tissue kallikrein with established functions, which include release
of Lys-bradykinin (kallidin) in inflammatory processes, such as
arthritis, asthma and rhinitis [4–6], and the processing of hormone
and other peptide precursors [1,2]. hK1, and the cognate enzymes
in mammals, release the vasoactive decapeptide Lys-bradykinin
(Lys-BK) by cleavage at Met379–Lys380 and Arg389–Ser390 in limited
proteolysis from high- and low-molecular-mass kininogens [7].
The only exceptions known so far are rat tissue kallikrein (rK1),
which cleaves a Lys–Arg bond and releases bradykinin from
bovine and rat kininogens [8,9], and mouse submandibular tissue
kallikrein [10], which also releases bradykinin. The efficiency
of cleavage at the Met–Lys bond by hK1 is dependent on
the extension of the substrates, as demonstrated by internally
quenched fluorescent peptides with the sequence of human
kininogen [11,12]. hK1 can also hydrolyse substrates that contain
a pair of phenylalanines, for example in the reactive-site loop of
hK1-binding protein, a specific serpin for tissue kallikrein called
Abbreviations used: hK1, human tissue kallikrein; Abz, o-aminobenzoic acid; EDDnp, N-(2,4-dinitrophenyl)ethylenediamine; MALDI–TOF MS, matrix-
assisted laser-desorption ionization–time-of-flight MS; PTI, pancreatic trypsin inhibitor; TFA, trifluoroacetic acid; λem, emission wavelength; λex, excitation
wavelength.
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kallistatin [13,14], as well as in somatostatin [15]. Although
hK1 possesses homology with trypsin, the crystal structures of
human and porcine tissue kallikrein [16,17] show that their S1
(see Schechter and Berger nomenclature [18]) sites are enlarged,
mainly owing to the insertion of an additional residue, Pro219,
which is in the cis configuration. This unique feature of tissue
kallikrein allows its S1 subsite to accept Arg, as well as a larger
and hydrophobic side chain, such as that of Phe.
In the present paper, we examined the S′1 and S′2 subsite
specificity of hK1, using the internally quenched fluorescent
peptide Abz-Ala-Ile-Lys-Phe-Phe-Ser-Arg-Gln-EDDnp as a
reference [where Abz is o-aminobenzoic acid and EDDnp is N-
(2,4-dinitrophenyl)ethylenediamine]; this peptide is a segment of
the reactive-centre loop sequence of kallistatin that has been used
previously for evaluation of hK1 specificity at non-prime subsites
[19]. Abz and EDDnp are the fluorescent donor and acceptor
groups respectively, and glutamine was introduced as a necessary
result of the solid-phase peptide synthesis strategy employed [20].
MATERIAL AND METHODS
Reagents
Homogeneous preparations of hK1, obtained as described
previously [21], were kindly provided by Dr J. Chao of the
Medical University of South Carolina, Charleston, SC, U.S.A.
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The molar concentrations of enzyme solutions were determined
by active-site titration with 4-nitrophenyl-4-guanidinobenzoate
[22].
Peptide synthesis
All the intramolecularly quenched fluorogenic peptides were
obtained by a solid-phase peptide synthesis strategy, the details
of which are provided elsewhere [20]. An automated bench-top
simultaneous multiple solid-phase peptide synthesizer (PSSM 8
system, Shimadzu, Tokyo, Japan) was used for the solid-phase
synthesis of all the peptides by the fluoren-9-ylmethoxycarbonyl
(Fmoc) procedure. The final deprotected peptides were purified
by semi-preparative HPLC using an Econosil C-18 column
(10 µm, 22.5 mm × 250 mm) and a two-solvent system: buffer
A, trifluoroacetic acid (TFA)/H2O (1:1000, v/v) and buffer B,
TFA/acetonitrile/H2O (1:900:100, by vol.). The column was
eluted at a flow rate of 5 ml/min with a 10–50% (or 30–60%)
gradient of solvent B over 30 or 45 min. Analytical HPLC
was performed using a binary HPLC system (Shimadzu) with
a SPD-10AV Shimadzu UV-Vis detector and a Shimadzu RF-535
fluorescence detector, coupled to an Ultrasphere C-18 column
(5 µm, 4.6 mm × 150 mm) which was eluted with solvent
systems A and B at a flow rate of 1 ml/min and a 10–80%
gradient of B over 20 min. The HPLC column eluates were moni-
tored by their absorbance at 220 nm and by fluorescence emission
at 420 nm following excitation at 320 nm. The molecular mass and
purity of synthesized peptides were checked by matrix-assisted
laser-desorption ionization–time-of-flight (MALDI–TOF) MS
(TofSpec-E; Micromass, Manchester, U.K.) and/or peptide
sequencing using a protein sequencer PPSQ-23 (Shimadzu).
Kinetic assays
Hydrolysis of the fluorogenic peptidyl substrates was performed
in 20 mM Tris/HCl and 1 mM EDTA, pH 9, at 37 ◦C and followed
by measuring the fluorescence at an emission wavelength (λem)
of 420 nm and an excitation wavelength (λex) of 320 nm in
a Hitachi F-2000 spectrofluorimeter. The 1 cm path length
cuvette, containing 2 ml of the substrate solution, was placed
in a thermostatically controlled cell compartment for 5 min
before the enzyme solution was added and the increase in flu-
orescence with time was continuously recorded for 10 min. The
slope was converted into mol of hydrolysed substrate/min,
based on the fluorescence curves of standard peptide solutions
before and after total enzymic hydrolysis. The concentration
of the peptide solutions was determined by colourimetric
determination of the 2,4-dinitrophenyl group (17300 M−1 · cm−1
molar absorption at 365 nm). The enzyme concentration for initial
rate determination was chosen at a level intended to hydrolyse
less than 5% of the substrate present. The kinetic parameters
were calculated according to Wilkinson [23], as well as by using
Eadie–Hofstee plots. All the obtained data were fitted to non-
linear least square equations using Grafit v 3.0 from Erithacus
Software.
Inhibition assay
The hydrolysis of the fluorogenic peptide substrate Pro-Phe-Phe-
7-methyl coumarine amide (Km = 70 µM, kcat = 12.5 s−1 [15];
where italics denote the D-form of the amino acid) was fol-
lowed by measuring the fluorescence at λem = 480 nm and λex =
360 nm in a Hitachi F-2000 spectrofluorimeter, at 37 ◦C in 20 mM
Tris/HCl, pH 9.0, containing 1 mM EDTA buffer. A 1 cm path
length cuvette containing 2 ml of 30 µM substrate solution was
placed in the thermostatted cell compartment for 5 min before the
enzyme solution was added to 0.5 nM final concentration, and the
increase in fluorescence with time (velocity) was continuously
recorded for up to 5 min. Small aliquots of a highly concentrated
inhibitor solution were added with minimal solution, and the
decreased velocity was read for up to 5 min to ensure that no more
than 5% of the initial substrate concentration was hydrolysed by
the end of the assay. The K i values for competitive inhibition
assays of the peptides were determined according to Nicklin and
Barrett [24].
Determination of cleaved bonds
The cleaved bonds were identified by isolation of the fragments by
HPLC and the retention times of the fluorescent Abz-containing
fragments were compared with authentic synthetic sequences
and/or by molecular mass, which was determined by MALDI–
TOF MS (TofSpec-E; Micromass).
RESULTS
P′1 position
The kinetic parameters for hydrolysis of the peptides derived
from the internally quenched fluorescent peptide Abz-Ala-Ile-
Lys-Phe-Phe-Ser-Arg-Gln-EDDnp with modifications at the P′1
position are presented in Table 1. We have previously reported
good substrates for hK1 with synthesized peptides derived from
this reference peptide [19], but with modifications at positions
P4–P1. Most of the peptides from the family presented here,
modified at the P′1 position, were poorly hydrolysed. In fact,
only substrates having Gln, Ser, Thr and Ile (peptides VI, VIII,
IX and X respectively) were hydrolysed to an extent that allowed
Table 1 Kinetic parameters and inhibiton constant (K i) for the simple linear
competitive inhibition of hK1 for the internally quenched fluorescent peptides
derived from the reactive centre loop of kallistatin, with modifications at the
P′1 position
Conditions: 20 mM Tris-HCl and 1 mM EDTA, pH 9, at 37 ◦C. *Poorly hydrolysed means that
at least 70 % of the initial peptide concentration (10 µM) remained intact after a 4-h incubation
period with 1 nM hK1 (the usual kinetic assay enzyme concentration). The cleavage point was
determined after an overnight incubation. †A resistant peptide was one that, for the former
conditions, presented a hydrolysis rate less than 10 %. ‡K i determined in 20 mM Tris/HCl and
1 mM EDTA, pH 9, at 37 ◦C over the hydrolysis of 20 µM Pro-Phe-Phe-methyl coumarine
amide (K m = 70 µM, k cat = 12.5 s −1 [15]), employing 1 nM hK1. Cleavage sites are indicated
with an arrow (↓).One-letter symbols have been used to represent amino acids and letters in
bold denote the mutated residue.
Abz-peptidyl- K m k cat k cat/K m K i‡
No. Glu-EDDnp (µM) (s−1) (mM · s)−1 (µM)
I AIKFF↓AR Poorly hydrolysed* 0.33 +− 0.02
II AIKFF↓ER Poorly hydrolysed* 0.40 +− 0.03
III AIKFF↓LR Poorly hydrolysed* 0.32 +− 0.01
IV AIKFF↓NR Poorly hydrolysed* 0.35 +− 0.05
V AIKFFPR Resistant† 0.090 +− 0.005
VI AIKFF↓QR 0.13 +− 0.01 0.02 +− 0.01 154 –
VII AIKFF↓RR Poorly hydrolysed* 0.21 +− 0.03
VIII AIKFF↓SR 0.36 +− 0.01 3.33 +− 0.15 9250 –
IX AIKFF↓TR 0.23 +− 0.02 0.04 +− 0.01 174 –
X AIKFF↓IR 0.27 +− 0.07 0.05 +− 0.01 185 –
XI AIKFF↓KR Poorly hydrolysed* 0.15 +− 0.01
XII AIKFF↓VR Poorly hydrolysed* 0.22 +− 0.02
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Table 2 Kinetic parameters and inhibition constants (K i) for the simple
linear competitive inhibition of hK1 for the internally quenched fluorescent
peptides derived from the reactive-centre loop of kallistatin, with
modifications at the P′2 position
Conditions: 20 mM Tris-HCl and 1 mM EDTA, pH 9, at 37 ◦C. *Poorly hydrolysed means
that at least 70 % of the initial peptide concentration (10 µM) remained intact after a 4-h
incubation period with 1 nM hK1 (the usual kinetic assay enzyme concentration). The cleavage
point was determined after an overnight incubation. †K i determined in 20 mM Tris/HCl, 1 mM
EDTA, pH 9, at 37 ◦C over the hydrolysis of 20 µM Pro-Phe-Phe-methyl coumarine amide
(K m = 70 µM, k cat = 12.5 s−1 [15]), employing 1 nM hK1. Cleavage sites are indicated with
an arrow (↓). One-letter symbols have been used to represent amino acids and letters in bold
denote the mutated residues.
Abz-peptidyl- K m k cat k cat/K m K i†
No. Glu-EDDnp (µM) (s−1) (mM · s)−1 (µM)
XIII AIKFF↓SA 1.79 +− 0.11 0.54 +− 0.01 302 –
XIV AIKFF↓SE Poorly hydrolysed* 0.51 +− 0.02
XV AIKFF↓SL Poorly hydrolysed* 0.19 +− 0.01
XVI AIKFF↓SN Poorly hydrolysed* 0.73 +− 0.04
XVII AIKFF↓SP 1.25 +− 0.26 0.05 +− 0.01 40 –
XVIII AIKFF↓SQ Poorly hydrolysed* 0.60 +− 0.05
XIX AIKFF↓SS 0.94 +− 0.12 0.30 +− 0.01 319 –
XX AIKFF↓ST Poorly hydrolysed* 0.32 +− 0.03
VIII AIKFF↓SR 0.36 +− 0.01 3.33 +− 0.15 9250 –
XXI AIKFF↓SI Poorly hydrolysed* 1.0 +− 0.1
XXII AIKFF↓SK 0.21 +− 0.03 0.12 +− 0.02 571 –
XXIII AIKFF↓SV Poorly hydrolysed* 1.7 +− 0.2
the determination of the kinetic parameters. All the other peptides
were recognized by hK1 and were able to effectively bind to the
active site of the enzyme, as indicated by the low K i values, and
limited hydrolysis was observed only after 4 h of incubation with
hK1. The K i values for the modifications at P′1 were approx.
0.30 µM. A proline residue at this position resulted in a peptide
(V), which was completely resistant to hydrolysis but was able
to inhibit hK1 with the lowest K i value throughout the series. It
is noteworthy that peptide VIII (containing a serine residue) was
hydrolysed with a specificity constant (kcat/Km) that was 50-fold
higher than other susceptible peptides containing Gln, Thr and
Ile (peptides VI, IX and X respectively), and this difference was
due mainly to the higher catalytic constant (kcat) of peptide VIII
hydrolysis.
P′2 position
The kinetic parameters for hydrolysis of the peptides derived from
the internally quenched fluorescent peptide Abz-Ala-Ile-Lys-Phe-
Phe-Ser-Arg-Gln-EDDnp, with modifications at the P′2 position,
are presented in Table 2. Although all the peptides of this family
contain Ser at P′1, which was the best amino acid residue at
this position, only the peptides with Arg, Ala, Pro, Ser and Lys
(VIII, XIII, XVII, XIX and XXII respectively in Table 2) were
hydrolysed with velocities that allowed the determination of the
kinetic parameters. The S′2 subsite of hK1 also seems to have a
specificity as restricted as that of its S′1 subsite for the hydrolysis of
peptide substrates. The most efficiently hydrolysed peptide was
the reference peptide (peptide VIII in Table 2), which contains
Arg at the P′2 position. All the poor substrates of this series were
assayed as competitive inhibitors, and the K i values ob-
tained were in the range 0.2–1.7 µM. The lowest K i value was
obtained with the peptide XV that contained Leu in the P′2
position.
Table 3 Determination of the inhibitory constant (K i) for the simple linear
competitive inhibition of human tissue kallikrein for peptides synthesized,
based on the kinetic parameters obtained from Tables 1 and 2
K i was determined using the following conditions: 20 mM Tris/HCl and 1 mM EDTA, pH 9, at
37 ◦C over the hydrolysis of 20 µM Pro-Phe-Phe-methyl coumarine amide (K m = 70 µM,
k cat = 12.5 s−1 [15]) with 1 nM hK1. One-letter symbols (with lowercase letters corresponding
to the D-form) have been used to denote amino acids.
No. Peptide K i (µM)
XXIV Abz-kFFPrQ-EDDnp 0.029 +− 0.001
XXV Abz-kFRPrQ-EDDnp 0.022 +− 0.001
XXVI Acetyl-kFRPrQ-EDDnp 0.424 +− 0.020
XXVII Acetyl-kFRPr-NH2 4.40 +− 0.08
XXVIII Acetyl-kFFPrQ-NH2 0.494 +− 0.015
XXIX Acetyl-kFFPLE-NH2 0.029 +− 0.004
Design of inhibitors
Table 3 presents the K i values for the peptides synthesized,
based upon the information gathered from Tables 1 and 2, and
from previously reported specificity studies at non-prime sites of
hK1 subsites [19]. In the peptides Abz-Lys-Phe-Phe-Pro-Arg-Gln-
EDDnp and Abz- Lys-Phe-Arg-Pro-Arg-Gln-EDDnp (XXIV and
XXV in Table 3; letters in italics denote the D-form of the amino
acid), Lys and Arg were introduced in their D-enantiomeric form
in order to provide resistance to hydrolysis and solubility to the
peptides. In addition, the Km values for the peptides containing
Lys at P3 positon [19] and Arg at P′2 (Table 2) were in the lower
range of the obtained values. The amino acid Phe was maintained
in the P2 position because it is present in the best synthetic short
substrates [25,26]. Phe or Arg were introduced at the P1 position
of these inhibitors in order to compare the fitting of these amino
acids at the S1 subsite of hK1. Pro was maintained in all peptides
because its presence at P′1 resulted in resistance of peptide V
and a low K i value (Table 1). Abz was substituted by an acetyl
group (peptides XXVI to XXIX), and the effects of Gln and
EDDnp were examined in peptides XXVII and XXVIII, in which
they were removed.
Arg and Phe at P1 in this setting of peptides have the same effect
in binding to the enzyme. The substitution of Abz with an acetyl
group increased the K i value one order of magnitude (compare
peptides XXV and XXVI). The C-terminal Gln-EDDnp seemed
to play a significant role in the binding of these peptides, because
the highest K i value was obtained with the peptide XXVII, in
which Gln-EDDnp is absent. When only EDDnp was removed
(compare peptides XXVI and XXVIII), no significant variation
was observed in the K i values. Finally, the peptide XXIX was
synthesized by replacing Leu and Glu-amide with D-Arg and
EDDnp respectively, and resulted in a inhibitor of hK1 with K i
of 0.029 µM, which is similar to values obtained for the peptides
XXIV and XXV (Table 3). Leu was introduced in peptide XXIX
because with this amino acid at P′2, the lowest Ki value was
obtained in the series shown in Table 2, and Glu was introduced
to substitute the negative environment provided by the two NO2
groups of EDDnp.
The inhibitory specificity activity of acetyl-Lys-Phe-Phe-Pro-
Leu-Glu-NH2 for hK1 was evaluated by comparing the inhibitory
effect of this peptide on human thrombin, activated factor X (FXa),
plasmin, trypsin, cathepsin G and plasma kallikrein. Surprisingly,
as shown in Table 4, human plasma kallikrein was inhibited by
acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH2 with a K i value which was
lower than that of hK1. All other proteases were less susceptible
to inhibition by this peptide.
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Table 4 Determination of the inhibition constant (K i) of acetyl-Lys-Phe-
Phe-Pro-Leu-Glu-NH2 on human serine proteases compared with hK1
Enzyme K i (nM)
Thrombin 700 +− 80
Factor Xa 130 +− 10
Plasmin 170 +− 11
Bovine trypsin NI*
Cathepsin G 170 +− 10
Human plasma kallikrein 8 +− 0.2
Human tissue kallikrein 29 +− 2
* No inhibition until 30 µM peptide concentration.
DISCUSSION
The specificities of the subsites S′1 and S′2 of hK1 play determinant
roles in the recognition and hydrolysis of substrates. The presence
of Ser and Arg at positions P′1 and at P′2 respectively, resulted
in the best substrate (Abz-Ala-Ile-Lys-Phe-Phe-Ser-Arg-Gln-
EDDnp) out of those derived from the kallistatin reactive-centre
loop sequence. Any other amino acid at P′1 or P′2 resulted in
peptides that were hydrolysed very slowly, and the kcat constants,
for those with values that could be determined, were at least
one order of magnitude lower than that of the hydrolysis of
Abz-Ala-Ile-Lys-Phe-Phe-Ser-Arg-Gln-EDDnp. It is noteworthy
that Lys-bradykinin (kallidin) is released by hK1 from human
kininogen, which is its natural substrate, by two cleavage events,
one faster with Ser at P′1 position for hydrolysis of Arg389–
Ser390 bond, and a second with Arg at P′2 for the hydrolysis of
Met379–Lys380 bond [11]. According to these observations, two
very efficient substrates for hK1 were described previously, Abz-
Phe-Arg-Ser-Arg-EDDnp (kcat = 5.7 s−1, Km = 0.15 µM, kcat/Km
= 38000 mM−1 · s−1) [27]), and the short internally quenched
fluorescent peptide Abz-Phe-Arg-Ser-EDDnp (kcat = 1.3 s−1,
Km = 0.28 µM, kcat/Km = 4643 mM−1 · s−1) [28]. In addition,
somatostatin was described as being hydrolysed at the Phe–Trp
bond by hK1 with Lys present at the P′2 position; however, an
efficient substrate derived from somatostatin was obtained by
putting Ser and Arg at P′1 and P′2 positions respectively, resulting
in the internally quenched fluorescent peptide Abz-Lys-Asn-Phe-
Phe-Ser-Arg-Gln-EDDnp (kcat = 2.5 s−1, Km = 0.29 µM, kcat/Km
= 8620 mM−1 · s−1) [19]. Therefore the specificities of S′1 and S′2
of tissue kallikrein seems to be as determinant as that of S2, which
requires hydrophobic, and preferentially aromatic, amino acids
[19,25] because of the hydrophobic crevice between Tyr99 and
Trp215 at the S′2 subsite of human and porcine tissue kallikrein
[16,17]. The S′1 and S′2 subsites of tissue kallikreins are not
well defined, although Ala and Lys in bovine pancreatic trypsin
inhibitor (PTI) occupy these subsites of porcine tissue kallikrein
in the crystal structure of the complex formed by them [17].
All together, these structural and kinetic observations suggest
that S′1 preferentially accepts residues with short side chains and
S′2 preferentially accepts residues with basic side chains. In the
described structure of PTI-tissue kallikrein complex, S′1 contains
a histidine residue that could establish convenient hydrogen
bonds with the serine side chain, and the basic residue of PTI
interacts with the main chain of the enzyme and is partially
exposed to solvent. In addition, the results presented in Tables 1
and 2 suggest that the occupancy of S′1 and S′2 hK1 subsites
determines whether a particular peptide will be preferentially a
substrate or an inhibitor. As some hydrolysis was detected with
most of the assayed peptides, an acyl–enzyme intermediate must
be formed with each peptide, but the amino leaving fragment
of those slowly hydrolysed peptides could stay in the hK1 for
a longer time, allowing a back reaction. This situation would be
similar to those observed for classical serine proteinase inhibitors,
where the favourable conditions of the back reaction seems to be
the main component for the high inhibitory activity of the classical
proteinaceous inhibitors [29]. In these inhibitors, the retention of
the amino fragment of the inhibitor is guaranteed by the rigidity of
the inhibitor–enzyme structure provided by a network of hydrogen
bonds inside the inhibitor. In the case of our small peptides, the
retention of the amino fragment could be a result of its strong
interaction with the prime subsites of hK1.
Using the information obtained with the peptides presented
in Tables 1 and 2, six peptides were designed as inhibitors
of hK1 (Table 3). Three out of the six peptides (Abz-Lys-
Phe-Phe-Pro-Arg-Gln-EDDnp, Abz-Lys-Phe-Arg-Pro-Arg-Gln-
EDDnp and acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH2) inhibited
hK1 in the range 20–30 nM. They were resistant to hydrolysis
by hK1 and, surprisingly, hK1 accepted Pro at S′1 and D-amino
acids at S3 and S′2 subsites. It is noteworthy that the inhibitory
activity of the peptide acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH2 was
due mainly to the presence of Glu at the S′3 position. This
result suggests that the negative side chain of Glu could be
playing the same role of the EDDnp, in which NO2 groups
introduce a strong polarization on this group and expose a
negative group that could interact favourably with hK1. The
peptide acetyl-Lys-Phe-Phe-Pro-Leu-Glu-NH2 inhibited other
serine proteases with higher K i values, apart from human plasma
kallikrein which has a K i value of 8 nM. This is a surprising
result, since this enzyme is known to be a restricted arginyl-
hydrolase, and a specific inhibitor of human plasma kallkrein
[30], PKSI-527 (trans-4-aminomethylcyclohexenecarbonyl-L-
phenylalanine-4-carboxymethylanilide), was described, which is
supposed to interact with the negatively charged S1 subsite
of human plasma kallikrein with the trans-4-aminomethyl-
cyclohexenecarbonyl moiety of the molecule. Although acetyl-
Lys-Phe-Phe-Pro-Leu-Glu-NH2 has the basic side chain of
D-lysine, it is not reasonable to propose that the lysine side chain
interacts with the S1 subsite of plasma kallikrein.
In conclusion, we report a restricted specificity of subsites S′1
and S′2 of hK1 and we also found a particular peptide sequence that
could be a leader compound to design specific inhibitor for hK1 or
for plasma kallikrein or for both at same time. The development
of compounds that inhibit both kallikreins could be of even more
interest if the inhibition of kinin release is the main goal.
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